Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KMDA
KMDA logo

KMDA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Kamada Ltd (KMDA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
8.470
1 Day change
52 Week Range
9.350
Analysis Updated At
2026/04/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Kamada Ltd (KMDA) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators are neutral, options data shows minimal trading activity, and the stock's short-term trend suggests potential downside. While the company has announced a dividend, its financial performance shows mixed results, with revenue growth but declining net income and gross margin. There are no strong catalysts or trading signals to justify immediate action.

Technical Analysis

The MACD is below zero and negatively contracting, indicating weak momentum. RSI is neutral at 58.199, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 8.33, with resistance at 8.624 and support at 8.037.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
5

Positive Catalysts

  • Eligible Nasdaq shareholders can benefit from a reduced withholding tax rate.

Neutral/Negative Catalysts

  • The stock has a 60% chance of declining by -2.8% in the next day, -3.95% in the next week, and -1.85% in the next month. Additionally, gross margin dropped by 13.01% YoY, and net income decreased by 6.46% YoY in Q4 2025.

Financial Performance

In Q4 2025, revenue increased by 14.54% YoY to $44.68 million. However, net income dropped by 6.46% YoY to $3.56 million, and gross margin decreased by 13.01% YoY to 37.98%. EPS remained flat at 0.06.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes were provided.

Wall Street analysts forecast KMDA stock price to rise
2 Analyst Rating
Wall Street analysts forecast KMDA stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.470
sliders
Low
13
Averages
14
High
15
Current: 8.470
sliders
Low
13
Averages
14
High
15
H.C. Wainwright
Buy
maintain
$11 -> $13
AI Analysis
2025-12-09
Reason
H.C. Wainwright
Price Target
$11 -> $13
AI Analysis
2025-12-09
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Kamada to $13 from $11 and keeps a Buy rating on the shares. The company decided to discontinue its Phase 3 inhaled alpha-1 antitrypsin deficiency clinical trial based on the results of the planned interim futility analysis, the analyst tells investors in a research note. The firm says the decision helps to refocus the company on its core products and eliminates a "long over-hanging distraction that was unlikely to be fruitful."

People Also Watch